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Impact of COVID-19 lockdown on the
incidence and mortality of acute
exacerbations of chronic obstructive
pulmonary disease: national interrupted
time series analyses for Scotland and Wales
Mohammad A. Alsallakh1,2*† , Shanya Sivakumaran1† , Sharon Kennedy3, Eleftheria Vasileiou2,4 , Ronan A. Lyons1 ,
Chris Robertson3,5 , Aziz Sheikh2,4 , Gwyneth A. Davies1,2 and on behalf of the EAVE II Collaborators
Abstract
Background: The COVID-19 pandemic and ensuing national lockdowns have dramatically changed the healthcare
landscape. The pandemic’s impact on people with chronic obstructive pulmonary disease (COPD) remains poorly
understood. We hypothesised that the UK-wide lockdown restrictions were associated with reductions in severe
COPD exacerbations. We provide the first national level analyses of the impact of the COVID-19 pandemic and first
lockdown on severe COPD exacerbations resulting in emergency hospital admissions and/or leading to death as
well as those recorded in primary care or emergency departments.
Methods: Using data from Public Health Scotland and the Secure Anonymised Information Linkage Databank in
Wales, we accessed weekly counts of emergency hospital admissions and deaths due to COPD over the first 30 weeks
of 2020 and compared these to the national averages over the preceding 5 years. For both Scotland and Wales, we
undertook interrupted time-series analyses to model the impact of instigating lockdown on these outcomes. Using
fixed-effect meta-analysis, we derived pooled estimates of the overall changes in trends across the two nations.
Results: Lockdown was associated with 48% pooled reduction in emergency admissions for COPD in both
countries (incidence rate ratio, IRR 0.52, 95% CI 0.46 to 0.58), relative to the 5-year averages. There was no
statistically significant change in deaths due to COPD (pooled IRR 1.08, 95% CI 0.87 to 1.33). In Wales,
lockdown was associated with 39% reduction in primary care consultations for acute exacerbation of COPD
(IRR 0.61, 95% CI 0.52 to 0.71) and 46% reduction in COPD-related emergency department attendances (IRR
0.54, 95% CI 0.36 to 0.81).
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Conclusions: The UK-wide lockdown was associated with the most substantial reductions in COPD
exacerbations ever seen across Scotland and Wales, with no corresponding increase in COPD deaths. This may
have resulted from reduced transmission of respiratory infections, reduced exposure to outdoor air pollution
and/or improved COPD self-management.
Keywords: Acute exacerbation of chronic obstructive pulmonary disease, COVID-19 lockdown
Background
The COVID-19 pandemic and subsequent challenges to
healthcare systems have led to unprecedented disrup-
tions of routine care for people with chronic conditions.
In response to a surge in COVID-19 cases, the UK and
devolved governments announced the first nationwide
lockdown on 23rd March 2020, thereby severely restrict-
ing movements and social contacts [1]. The accompany-
ing messages to avoid overwhelming the National Health
Service (NHS) and fear of contracting SARS-CoV-2 in
healthcare settings had an impact on people’s willingness
to seek emergency care [2].
There is evidence that the UK-wide lockdown was asso-
ciated with poorer cardiovascular [3] and cancer [4] out-
comes, but its impact on serious chronic obstructive
pulmonary disease (COPD) outcomes remains unclear.
Despite the disruption to routine COPD care [5, 6],
the societal changes associated with lockdown—in par-
ticular, improvements in air quality and reductions in
other viruses responsible for acute respiratory tract in-
fections [7, 8]—may have led to an overall improvement
in COPD outcomes. The available body of evidence sug-
gests that there may have been a reduction in acute ex-
acerbations of COPD (AECOPD), but these data are
difficult to interpret because of methodological limita-
tions including studying selective populations and/or
from a limited number of centres [9–26]. Despite the
changes in healthcare-seeking behaviour during the
lockdown, people with severe AECOPD were still likely
to seek medical attention as the symptoms are intense
such that they are difficult to tolerate at home [12].
We sought to investigate the impact of the UK-wide
COVID-19 lockdown on the overall numbers of recorded se-
vere AECOPDs leading to admission and/or death across
the entire populations of Scotland and Wales. To contextual-
ise the findings, we also investigate AECOPDs that were re-
corded in primary care and emergency departments (EDs) in
Wales.
Methods
Data sources, populations and case definitions
The study was based on the entire populations of
Scotland and Wales (the 2019 mid-year population esti-
mates were 5,463,300 and 3,152,900, respectively). We
accessed complete coverage person-level datasets from
Public Health Scotland (PHS) [27] and the Secure Anon-
ymised Information Linkage (SAIL) Databank [28] in
Wales. PHS receives individual-level data from all gen-
eral or acute specialties in NHS hospitals in Scotland.
The SAIL Databank receives linkable, routinely collected
data from all NHS hospitals in Wales and 80% of general
practices as well as other healthcare and administrative
data.
We defined two primary outcome measures relating to
severe COPD exacerbations: COPD-related emergency
hospital admission, and death due to COPD. Emergency
admissions for COPD were defined as those with a pri-
mary diagnosis of COPD recorded using the J43 and J44
codes of the 10th revision of the International Statistical
Classification of Diseases (ICD-10). These data were ex-
tracted from the Scottish Morbidity Record 01 (SMR01)
and the Patient Episodes Database for Wales (PEDW),
both of which undergo regular data quality checks [29,
30]. In Wales, we also extracted the average length of
stay (LOS) of COPD admissions.
Deaths due to COPD were defined as those with
COPD (ICD-10 codes of J43 and J44) as the underlying
cause of death in the National Records of Scotland
(NRS) deaths database or the Annual District Death Ex-
tract (ADDE) in SAIL. Mortality data were regularly
checked and validated by the UK Office for National Sta-
tistics (ONS) [31–33].
In Wales, we also had access to primary care and ED
data. We defined COPD-related ED attendances as those
with a COPD code (14B) as the primary diagnosis in the
Emergency Department Dataset (EDDS) in SAIL. We
defined a general practitioner-recorded AECOPD from
the Welsh Longitudinal General Practice (WLGP) data-
set in SAIL as an AECOPD code preceded by a COPD
diagnosis code. The code sets are included in the supple-
mentary information.
Statistical analyses
We visualised the trends of the aforementioned out-
comes for the first 30 calendar weeks in 2020 and corre-
sponding national averages for the preceding 5 years. To
investigate the impact of the UK lockdown on these out-
comes, we undertook interrupted time series analyses
with a single change point of the 23rd of March (week
13). We modelled the trends in the first 30 calendar
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weeks in 2020 and the corresponding 5-year averages
(2015–2019) using Poisson generalised linear regression
in R 4.0.3. The initial change point model in both the
baseline period and 2020 had a pre-lockdown slope and
intercept as well as an instantaneous change in intercept
at the week of lockdown and a change in slope following
lockdown. In the baseline period, we were anticipating
no change in intercept and no change in slope at week
13. The final model was based upon the baseline and
2020 data and included a binary variable to differentiate
the two periods, together with interaction terms for the
slopes and instantaneous effects of lockdown. These
interaction terms were used to compare the slopes prior
to lockdown in the baseline period with 2020, to com-
pare the instantaneous change in intercept at lockdown
in baseline with 2020 and to compare the change in
slope post-lockdown in baseline with 2020. Residual
plots were used to check the linearity assumption, and
the Breusch-Godfrey test [34] was used to assess auto-
correlation. Separate models were used in Scotland and
Wales, and z tests were used to compare the model coef-
ficients between the two countries. We then used fixed-
effect meta-analysis to derive pooled estimates from
their weighted averages.
In pre-specified sensitivity analyses, we restricted the
definition of the study outcomes in Wales to people
aged at least 35 years with a smoking history (current or
former smokers) documented in the Welsh Longitudinal
General Practice (WLGP) dataset. Linkage to the WLGP
dataset was available within the SAIL Databank through
the Anonymised Linkage Field (ALF) [35]. We excluded
records with missing ALF field or low-quality linkage.
For COPD admissions in Wales, we compared length
of stay over the weeks 13 to 30 between 2020 and the 5-
year average using a separate Poisson model controlled
for week number. We used beta regression to model the
relationship between the year of admission and the pro-
portion of COPD admissions during which patients died
due to COPD in every week, with week number as a
covariate.
Data analysis was performed in R 4.0.2.
Reporting guidelines
We followed the Framework for Enhanced Reporting of
Interrupted Time Series (FERITS) [36] and the REport-
ing of studies Conducted using Observational Routinely
collected Data (RECORD) statement [37] in the report-
ing of this study (see the Supplementary Materials).
Role of the funding source
The funders had no role in the study design, data collec-
tion and analysis, interpretation of findings, writing of




In the first 30 weeks of 2020, there were a total of 9847
emergency admissions for COPD in Scotland (6786) and
Wales (3061). Those admissions were consistently lower
than the averages of the corresponding periods in the
preceding 5 years in both countries (Fig. 1).
In Scotland, the slope before lockdown in 2020 was
decreasing (IRR 0.97, 95% CI 0.96 to 0.98), although
there was no evidence that this slope differed from the
5-year average (IRR 1.00, 95% CI 0.98 to 1.01). Introdu-
cing lockdown in week 13 was associated with a reduc-
tion in admissions by 48% (IRR 0.52; 95% CI 0.47 to
0.58). This reduction was 52% greater than the average
change at the same point in the preceding 5 years (IRR
0.48; 95% CI 0.42 to 0.55). The slope of admissions then
gradually increased over the coming weeks (IRR 1.05,
95% CI 1.04 to 1.07), which was in contrast to the slope
of the 5-year average which was decreasing (Fig. 1 and
Table 1).
In Wales, admissions in the first 12 weeks of 2020
were falling (IRR 0.94, 95% CI 0.92 to 0.95), slightly fas-
ter than the corresponding 5-year average (IRR 0.96,
95% CI 0.95 to 0.98). Introducing lockdown in week 13
was associated with a 38% reduction in admissions (IRR
0.62, 95% CI 0.53 to 0.72). This reduction was 40%
greater than the average change at the same point in the
preceding 5 years (IRR 0.60; 95% CI 0.50 to 0.73). Simi-
lar to the pattern seen in Scotland, there was a slight
gradual increase in the slope of admissions over the en-
suing weeks (IRR 1.07, 95% CI 1.05 to 1.09), which con-
trasted with the decreasing slope in the 5-year average
(Fig. 1 and Table 1). Admissions for COPD were 22%
shorter in 2020 during lockdown than in the corre-
sponding periods in the preceding 5 years (IRR 0.78,
95% CI 0.78 to 0.79, p value < 0.001). However, there
was no evidence that the proportion of COPD admis-
sions during which patients died due to COPD in the
weeks 13 to 30 was different in 2020 than the corre-
sponding periods of the preceding 5 years (odds ratio
1.05, 95% CI 0.77 to 1.43, p value 0.756).
The estimated effects in Wales did not change signifi-
cantly after restricting the analysis to those aged ≥ 35
years at admission with a smoking history (Table B,
Additional file 1).
There was a 48% pooled reduction in admissions dur-
ing lockdown across Scotland and Wales (IRR 0.52, 95%
CI 0.46 to 0.58).
Deaths
There were a total of 2554 deaths with COPD as the
underlying cause in Scotland (1535) and Wales (1019) in
the first 30 weeks of 2020.
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In 2020 before lockdown, the trend of deaths with
COPD as the underlying cause was not significantly dif-
ferent from the 5-year average (Fig. 2). The slope of
deaths during this period was falling slightly in both na-
tions (Scotland: IRR 0.98, 95 %CI 0.96 to 1.00; Wales:
IRR 0.97, 95% CI 0.94 to 0.99, Table 2), as it did in the
corresponding 5-year average.
There was no statistically significant change in deaths
following the introduction of lockdown at week 13 of
2020 nor at the same point in the 5-year average in both
nations (in Scotland, IRR in 2020 relative to 5-year aver-
age: 1.07, 95% CI 0.81 to 1.41; in Wales, IRR 1.09, 95%
CI 0.78 to 1.53; pooled IRR: 1.08, 95% CI 0.87 to 1.33).
Deaths during the lockdown continued to fall, similar
to the same period in the 5-year average (Fig. 2).
The estimated effects in Wales did not change after
restricting the analysis to those with a smoking history who
died at the age of ≥ 35 years (Table C, Additional file 1).
Primary care consultations
In Wales, there were 4575 primary care consultations
for AECOPD in the first 30 weeks of 2020. Before
lockdown, consultations were declining (IRR 0.93,
95% CI 0.92 to 0.94) in a steeper slope than the 5-
year average (IRR 0.96, 95% CI 0.95 to 0.97, Table 3
and Fig. 3). Introducing lockdown was associated with
Fig. 1 Weekly count of emergency COPD admissions in Scotland and Wales in 2020 and the corresponding 5-year averages (2015–2019, points)
in addition to modelled trend lines
Table 1 Poisson models of emergency COPD admissions in 2020 and the corresponding 5-year averages (2015-2019).
Scotland Wales Pooled estimates
IRR (95% CI) p value IRR (95% CI) p value IRR (95% CI) p value
Pre-lockdown intercept in 2020 compared to 5-year average 0.83 (0.75, 0.91) < 0.001 0.59 (0.51, 0.67) < 0.001 0.74 (0.68, 0.80) < 0.001
Slope in weeks 1–12
5-year average 0.97 (0.97, 0.98) < 0.001 0.97 (0.96, 0.98) < 0.001 0.97 (0.97, 0.98) < 0.001
2020 0.97 (0.96, 0.98) < 0.001 0.94 (0.92, 0.95) < 0.001 0.96 (0.95, 0.97) < 0.001
2020 relative to 5-year average 1.00 (0.98, 1.01) 0.686 0.96 (0.95, 0.98) < 0.001 0.99 (0.98, 1.00) 0.006
Change in level at week 13
5-year average 1.08 (1.00, 1.18) 0.056 1.02 (0.92, 1.15) 0.666 1.06 (0.99, 1.13) 0.072
2020 0.52 (0.47, 0.58) < 0.001 0.62 (0.53, 0.72) < 0.001 0.55 (0.50, 0.60) < 0.001
2020 relative to 5-year average 0.48 (0.42, 0.55) < 0.001 0.60 (0.50, 0.73) < 0.001 0.52 (0.46, 0.58) < 0.001
Change in slope after week 13
5-year average 1.01 (1.00, 1.02) 0.023 1.01 (1.00, 1.03) 0.034 1.01 (1.00, 1.02) 0.002
2020 1.05 (1.04, 1.07) < 0.001 1.07 (1.05, 1.09) < 0.001 1.06 (1.05, 1.07) < 0.001
2020 relative to 5-year average 1.04 (1.03, 1.06) < 0.001 1.06 (1.03, 1.08) < 0.001 1.05 (1.03, 1.06) < 0.001
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a 39% instantaneous reduction in those consultations
after adjusting for the 5-year averages (IRR 0.61, 95%
CI 0.52 to 0.71). After week 13 of 2020, the slope
continued to decline although it was less steep than
the pre-lockdown slope (IRR for change in slope:
1.03, 95% CI 1.01 to 1.04). The estimated effects did
not change after restricting the analysis to those with
a smoking history who died at the age of ≥ 35 years
(Table D, Additional file 1).
Emergency department attendances
In Wales, there were 625 COPD-related ED attendances in
the first 30 weeks of 2020. These events were consistently
lower in the weeks 1 to 30 in 2020 than in the same period
of the preceding 5 years (Fig. 4). There was no clear trend
before lockdown (IRR 0.97, 95% CI 0.94 to 1.01, Table 4),
unlike the corresponding slope in the baseline period which
was decreasing. Introducing lockdown was associated with
a 46% fall in attendances compared with the 5-year aver-
ages (IRR 0.54, 95% CI 0.36 to 0.81). After week 13 of 2020,
there was an upward slope (IRR for change in slope: 1.05,
95% CI 1.01 to 1.09), unlike the corresponding slope in the
baseline period which continued to decrease. The estimated
effects did not change after restricting the analysis to those
with a smoking history who died at the age of ≥ 35 years
(Table E, Additional file 1).
Discussion
Our national level interrupted time-series analyses of the
impact of lockdown across Scotland and Wales found
substantial reductions in severe AECOPD leading to ED
attendance and/or hospital admission as well as the less
Fig. 2 Weekly count of deaths with COPD as the underlying cause in Scotland and Wales in 2020 and the corresponding 5-year averages (2015–
2019, points) in addition to modelled trend lines
Table 2 Poisson models of deaths with COPD as the underlying cause in 2020 and the corresponding 5-year averages (2015–2019).
Scotland Wales Pooled estimates
IRR (95% CI) p value IRR (95% CI) p value IRR (95% CI) p value
Pre-lockdown intercept in 2020 compared to 5-year average 0.87 (0.70, 1.08) 0.206 0.85 (0.66, 1.11) 0.234 0.86 (0.73, 1.02) 0.083
Slope in weeks 1–12
5-year average 0.96 (0.94, 0.98) < 0.001 0.98 (0.96, 1.00) 0.063 0.97 (0.95, 0.98) < 0.001
2020 0.98 (0.96, 1.00) 0.042 0.97 (0.94, 0.99) 0.004 0.97 (0.96, 0.99) 0.001
2020 relative to 5-year average 1.02 (0.99, 1.05) 0.240 0.99 (0.95, 1.02) 0.446 1.00 (0.98, 1.03) 0.673
Change in level at week 13
5-year average 1.02 (0.84, 1.22) 0.869 0.95 (0.75, 1.20) 0.657 0.99 (0.86, 1.14) 0.883
2020 1.09 (0.89, 1.33) 0.417 1.03 (0.81, 1.32) 0.803 1.06 (0.91, 1.24) 0.432
2020 relative to 5-year average 1.07 (0.81, 1.41) 0.627 1.09 (0.78, 1.53) 0.627 1.08 (0.87, 1.33) 0.494
Change in slope after week 13
5-year average 1.02 (1.00, 1.04) 0.084 0.99 (0.97, 1.02) 0.687 1.01 (0.99, 1.03) 0.266
2020 0.99 (0.97, 1.01) 0.411 0.99 (0.96, 1.02) 0.699 0.99 (0.97, 1.01) 0.379
2020 relative to 5-year average 0.97 (0.94, 1.00) 0.078 1.00 (0.96, 1.04) 0.997 0.98 (0.96, 1.01) 0.169
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severe AECOPD that are recorded in primary care. The
levels remained well below the corresponding 5-year aver-
ages throughout the study period. The easing of strict
lockdown restrictions announced at the end of May 2020
[38, 39] did not lead to a substantial rebound in these
events, but there was a gradual rise in ED attendances and
admissions. There was no evidence of an increase in
deaths due to COPD during the lockdown.
These findings are especially significant given that
COPD exacerbations are one of the commonest reasons
for emergency admission to hospital [40]. Reduced inci-
dence of AECOPDs therefore increases healthcare
capacity and resources available for those with COVID-
19, as well as conferring obvious benefits to people with
COPD. A reduction in AECOPD admissions is also par-
ticularly advantageous given the specific challenges in the
hospital management of AECOPD during the pandemic—
components of care, such as non-invasive ventilation
(NIV), are associated with increased risk of viral transmis-
sion due to aerosolization [41] and can therefore only be
delivered in specified clinical areas.
To the best of our knowledge, this is the first national
level analysis of the impact of the COVID-19 lockdown
on AECOPD incidence and mortality, using data across
Table 3 Poisson models of primary care consultations for acute exacerbations of COPD in Wales in 2020 and the corresponding 5-
year averages (2015–2019)
IRR (95% CI) p value
Pre-lockdown intercept in 2020 compared to 5-year average 0.76 (0.68, 0.86) < 0.001
Slope in weeks 1–12
5-year average 0.97 (0.96, 0.98) < 0.001
2020 0.93 (0.92, 0.94) < 0.001
2020 relative to 5-year average 0.96 (0.95, 0.97) < 0.001
Change in level at week 13
5-year average 1.05 (0.95, 1.16) 0.322
2020 0.64 (0.56, 0.72) < 0.001
2020 relative to 5-year average 0.61 (0.52, 0.71) < 0.001
Change in slope after week 13
5-year average 1.01 (1.00, 1.02) 0.043
2020 1.03 (1.01, 1.04) < 0.001
2020 relative to 5-year average 1.01 (1.00, 1.03) 0.147
Fig. 3 Weekly count of primary care consultations for acute
exacerbation of COPD in Wales in 2020 and the corresponding 5-year
averages (2015–2019, points) in addition to modelled trend lines
Fig. 4 Weekly count of COPD-related emergency department
attendances in Wales in 2020 and the corresponding 5-year
averages (2015–2019, points) in addition to modelled trend lines
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primary and secondary care as well as data on deaths.
We used population-based data with high-to-complete
geographical coverage across Scotland and Wales, which
enabled comparison of findings between the two UK na-
tions, which were broadly comparable.
Our study has some limitations. Firstly, there are no
validated case definitions for COPD admissions or
deaths in UK data, and so the case definitions used may
have variable accuracy. We did not include deaths with
COPD as a contributing cause because they would not
have been specific enough for the purpose of this study.
Data on AECOPD in primary care and ED data is
under-recorded [42, 43]. However, our sensitivity ana-
lysis, limiting data to those aged ≥ 35 and ever-smokers,
did not impact our overall results. Further, given that we
were interested in trends over time rather than absolute
numbers and that coding practices of these events are
unlikely to have changed, this is unlikely to have signifi-
cantly affected our findings.
The observed reduction in AECOPDs during lockdown
does not necessarily imply direct causal effects of lock-
down. Nonetheless, they are likely to have been mediated
by reductions in the transmission of other respiratory
pathogens and outdoor air pollution during lockdown [7,
8, 14], both of which have a major role in triggering
AECOPD [44]. These factors could also have mediated
the reductions in emergency admissions for asthma that
have been reported following lockdowns [45–48].
A number of potential confounding factors such as
changes in prescribing for COPD [49], behavioural
changes related to improved self-management and
smoking reduction/cessation [50], and possibly improved
air quality [7] during the first wave of pandemic might
have contributed to the observed reduction in
AECOPDs. However, we were not in a position to adjust
for these potential sources of bias. Care therefore needs
to be taken when interpreting our findings. Furthermore,
national messaging on the need to avoid overwhelming
the NHS and the fear about the spread of SARS-CoV-2
might have contributed to the fall in AECOPD-related
ED attendances and admissions during the first wave of
the pandemic. However, this effect on healthcare-
seeking behaviour is likely limited in those experiencing
a severe AECOPD, which usually requires hospital as-
sessment and treatment. In addition, the corresponding
decline in AECOPD in primary care records suggests a
true decline in incidence during lockdown. However, it
is possible that the milder forms of AECOPDs have been
self-managed by patients and were not presented to the
health care system during lockdown.
The lifting of restrictions on travel and social contact
was associated with a gradual rise in emergency admis-
sions for AECOPD seen in our data for Scotland and
Wales. This could be partly due to an increase in the cir-
culation of respiratory viruses (mainly rhinoviruses ini-
tially) [8] and levels of outdoor air pollutants [51].
However, this could also be explained by an increasing
threshold of hospital admission, since primary care con-
sultations for AECOPD continued to fall towards sum-
mer in accordance with the typical seasonal trend of
AECOPD in the UK [52].
Although there is extensive literature on COPD as a
risk factor for COVID-19 severe outcomes and deaths
[53–55], there is currently limited data examining how
the pandemic, and specifically lockdowns, has affected
COPD deaths more widely. Two studies from Hong
Kong and England reported no difference in inpatient
mortality during admissions for COPD exacerbation [13,
Table 4 Poisson models of COPD-related emergency department attendances in Wales in 2020 and the corresponding 5-year
averages (2015–2019)
IRR (95% CI) p value
Pre-lockdown intercept in 2020 compared to 5-year average 0.65 (0.48, 0.88) 0.006
Slope in weeks 1–12
5-year average 0.97 (0.94, 0.99) 0.006
2020 0.97 (0.94, 1.01) 0.101
2020 relative to 5-year average 1.01 (0.97, 1.05) 0.686
Change in level at week 13
5-year average 1.08 (0.85, 1.38) 0.508
2020 0.59 (0.42, 0.82) 0.002
2020 relative to 5-year average 0.54 (0.36, 0.81) 0.003
Change in slope after week 13
5-year average 1.02 (0.99, 1.05) 0.227
2020 1.05 (1.01, 1.09) 0.019
2020 relative to 5-year average 1.03 (0.98, 1.08) 0.256
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15]. Analysis of excess mortality from specific conditions
is important in understanding whether reductions in
emergency healthcare utilisation represent a true reduc-
tion in incidence or avoidance of healthcare settings, the
latter of which could lead to increased mortality. Our
study has shown no significant increase in non-COVID
COPD deaths over the first 30 weeks of 2020. This is in
contrast to a recent analysis of cardiovascular mortality
in England and Wales [3], which demonstrated excess
non-COVID acute cardiovascular deaths. The authors
suggested that people with these diagnoses either did
not seek help for their illness or were not referred to
hospital, consistent with the greatest proportional in-
crease in cardiovascular deaths occurring in community
settings. Data from England from March to September
2020 from the Office for National Statistics shows that
COVID-19 accounted for over 90% of excess deaths
among those aged over 75 from both sexes, but the pro-
portion of non-COVID excess deaths was higher across
younger people [56]. The leading causes of these non-
COVID excess deaths were dementia, ischaemic heart
disease, cerebrovascular disease and other circulatory
diseases. Deaths in England due to “chronic lower re-
spiratory diseases” (ICD-10 codes J40-47) including
COPD actually fell compared to expected levels when
assessed cumulatively from March to September 2020
[56], consistent with our findings in Scotland and Wales.
There are several important areas for future investiga-
tion to understand underlying reasons for our findings.
These include person-level analyses of how factors re-
lated to COPD, such as disease severity, control and
health service utilisation and positive drivers such as re-
duced exposure to respiratory pathogens and pollutants,
improved self-management, smoking cessation and other
behavioural changes, might have affected the risk of
AECOPD and related death during lockdown. If further
work suggests that altered outdoor air pollution levels
have played a significant role, findings should spur in-
creased drive to improve air quality longer term [57].
Other interventions with the potential to produce lasting
reductions in the rate of severe AECOPD include the fa-
cilitation of self-management of chronic conditions and
the consolidation of public health messages to reduce
the transmission of respiratory infections, including
hand hygiene, use of facemasks and wider deployment of
testing and isolation when viruses are most likely to be
circulating.
Conclusions
We found significant declines in AECOPDs across pri-
mary and secondary care in Scotland and Wales during
the initial UK-wide lockdown in 2020, with no associ-
ated increase in non-COVID deaths due to COPD. Our
study strengthens the notion that outcomes relating to
chronic respiratory disease improved during the lock-
down period. It is crucial to assess the fuller impact of
the pandemic on care and outcomes in chronic health
conditions such as COPD, including non-COVID related
morbidity and mortality. This will inform the targeting
of public health strategy to minimise any adverse effects
as well as capture any positive elements that could be
harnessed to reduce hospital admissions in vulnerable
groups over the longer term.
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